Apellis Pharmaceuticals, Inc.

NasdaqGS:APLS Stock Report

Market Cap: US$3.8b

Apellis Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:APLS Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
21 Jan 25SellUS$21,420James ChopasIndividual715US$29.96
17 Jan 25SellUS$37,178Karen LewisIndividual1,241US$29.96
17 Jan 25SellUS$55,513Caroline BaumalIndividual1,853US$29.96
17 Jan 25SellUS$36,998Mark DelongIndividual1,235US$29.96
17 Jan 25SellUS$179,959Cedric FrancoisIndividual6,007US$29.96
17 Jan 25SellUS$22,469Pascal DeschateletsIndividual750US$29.96
17 Jan 25SellUS$64,260Nur NicholsonIndividual2,145US$29.96
17 Jan 25SellUS$65,938Adam TownsendIndividual2,201US$29.96
17 Jan 25SellUS$51,828Timothy SullivanIndividual1,730US$29.96
17 Jan 25SellUS$65,938David WatsonIndividual2,201US$29.96
13 Jan 25SellUS$45,895Mark DelongIndividual1,599US$28.70
13 Jan 25SellUS$7,577Jeffrey EiseleIndividual264US$28.70
13 Jan 25SellUS$65,670Pascal DeschateletsIndividual2,288US$28.70
13 Jan 25SellUS$179,302Cedric FrancoisIndividual6,247US$28.70
13 Jan 25SellUS$45,895Karen LewisIndividual1,599US$28.70
13 Jan 25SellUS$75,544Nur NicholsonIndividual2,632US$28.70
13 Jan 25SellUS$142,506David WatsonIndividual4,965US$28.70
13 Jan 25SellUS$77,065Adam TownsendIndividual2,685US$28.70
13 Jan 25SellUS$22,474James ChopasIndividual783US$28.70
06 Jan 25SellUS$95,215Caroline BaumalIndividual2,816US$33.81
23 Dec 24SellUS$2,085Jeffrey EiseleIndividual63US$33.09
11 Dec 24SellUS$171,175David WatsonIndividual5,000US$34.24
16 Sep 24SellUS$6,952James ChopasIndividual192US$36.21
03 Sep 24SellUS$21,720James ChopasIndividual550US$39.49
19 Mar 24SellUS$1,068,161Epidarex CapitalCompany18,681US$57.18
18 Mar 24SellUS$564,050Mark DelongIndividual9,913US$56.90
15 Mar 24SellUS$10,389James ChopasIndividual184US$56.46
13 Mar 24SellUS$645,838Nur NicholsonIndividual11,220US$58.13
12 Feb 24SellUS$40,457Mark DelongIndividual597US$67.77
12 Feb 24SellUS$96,974Timothy SullivanIndividual1,431US$67.77
12 Feb 24SellUS$77,796Adam TownsendIndividual1,148US$67.77
12 Feb 24SellUS$52,926David WatsonIndividual781US$67.77
12 Feb 24SellUS$268,492Cedric FrancoisIndividual3,962US$67.77
12 Feb 24SellUS$77,796Pascal DeschateletsIndividual1,148US$67.77
29 Jan 24SellUS$23,539Mark DelongIndividual367US$64.14
29 Jan 24SellUS$17,895Jeffrey EiseleIndividual279US$64.14
29 Jan 24SellUS$182,345Cedric FrancoisIndividual2,843US$64.14
29 Jan 24SellUS$56,057Pascal DeschateletsIndividual874US$64.14
29 Jan 24SellUS$58,109Adam TownsendIndividual906US$64.14
29 Jan 24SellUS$58,109David WatsonIndividual906US$64.14
29 Jan 24SellUS$53,555Nur NicholsonIndividual835US$64.14
29 Jan 24SellUS$58,109Timothy SullivanIndividual906US$64.14
29 Jan 24SellUS$23,539Karen LewisIndividual367US$64.14

Insider Trading Volume

Insider Buying: APLS insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of APLS?
Owner TypeNumber of SharesOwnership Percentage
State or Government45,6250.0334%
Individual Insiders4,388,3003.22%
VC/PE Firms12,806,3429.38%
Hedge Funds23,001,95416.9%
Institutions96,220,01670.5%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 91.49% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
12.5%
Wellington Management Group LLP
15,566,969US$473.1m-5.01%0.07%
10.3%
The Morningside Group Limited
12,806,342US$389.2m0%29.2%
9.56%
EcoR1 Capital, LLC
11,890,843US$361.4m2.44%13.8%
8.93%
Avoro Capital Advisors LLC
11,111,111US$337.7m0%4.78%
7.89%
The Vanguard Group, Inc.
9,815,575US$298.3m0.06%no data
4.98%
BlackRock, Inc.
6,192,368US$188.2m6.85%no data
4.82%
Deep Track Capital, LP
6,000,000US$182.3m36.3%5.77%
3.25%
State Street Global Advisors, Inc.
4,040,861US$122.8m-2.55%no data
3.06%
JP Morgan Asset Management
3,808,257US$115.7m21.6%0.01%
2.7%
T. Rowe Price Group, Inc.
3,363,728US$102.2m-36.8%0.01%
2.64%
Morgan Stanley, Investment Banking and Brokerage Investments
3,281,668US$99.7m62.8%0.01%
2.51%
Braidwell LP
3,125,183US$95.0m411%4.3%
2.42%
Octagon Capital Advisors LP
3,006,980US$91.4m4.38%15.23%
2.33%
FMR LLC
2,896,894US$88.0m-12.2%no data
1.74%
Artal Group S.A.
2,167,224US$65.9m47.7%2.03%
1.46%
Jennison Associates LLC
1,821,115US$55.3m-49.3%0.03%
1.46%
Geode Capital Management, LLC
1,810,526US$55.0m1.26%no data
1.41%
Cedric Francois
1,748,023US$53.1m-4.7%no data
1.39%
Tavistock Life Sciences
1,726,000US$52.5m0%3.88%
1.38%
Deutsche Asset & Wealth Management
1,722,372US$52.3m-5.34%0.01%
1.09%
Fiera Capital Corporation
1,354,469US$41.2m-3.33%0.09%
1.02%
OrbiMed Advisors LLC
1,270,400US$38.6m-2.49%0.55%
0.9%
Pascal Deschatelets
1,119,057US$34.0m0.46%no data
0.87%
Polar Capital Holdings Plc
1,082,000US$32.9m0.24%0.11%
0.87%
Norges Bank Investment Management
1,079,605US$32.8m0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/23 05:12
End of Day Share Price 2025/01/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Apellis Pharmaceuticals, Inc. is covered by 34 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Michael UlzBaird
Ishan MajumdarBaptista Research